Tvardi Therapeutics Stock Forecast
NASDAQ: TVRDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 1.03 0.00%
TVRD analyst consensus
Consensus (9 analysts)
buy
Avg. price target
$9.25+798.06%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Tvardi Therapeutics (2026-10-09), 7 rate the stock a buy or strong buy, 1 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $9.25, with a high estimate of $14.00 and a low estimate of $3.00. The average target implies upside of 798.1% from the current price of $1.03.
The spread between the highest and lowest targets is 366.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TVRD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 22% |
| Buy | 5 | 56% |
| Hold | 1 | 11% |
| Sell | 0 | 0% |
| Strong sell | 1 | 11% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.00 | +191.26% |
| Average target | $9.25 | +798.06% |
| High target | $14.00 | +1259.22% |